Carestream Dental, LLC
$175.9K 410 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
VisionCare Inc.
VisionCare Inc. reported $175,574.56 across General Payments, Research, and Ownership to 86 physicians and teaching hospitals across 86 transactions.
- $175.6K Below-median payer
- All-tracks total
- 86 Below-median volume
- Transactions
- 86 Below-median reach
- Recipients
- +$106.7K
- General Payments vs PY2023
VisionCare Inc. reported $175,574.56 across all CMS Open Payments tracks (General + Research + Ownership) to 86 physicians and teaching hospitals in Program Year 2024 - ranking #1044 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $175,574.56, averaging $2.0K per recipient.
VisionCare Inc.'s payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
14/100
Total payments
F
12/100
Transaction volume
F
11/100
Physician reach
F
11/100
Payment type diversity
F
23/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer visioncare-inc VisionCare Inc.
$175.6K · #1044/1,925 · 0.0% industry · PY2024
- TOT $175.6K
- RANK #1044
- SHARE 0.0%
- TXN 86
- RCP 86
- CAT 2
- GEN $175.6K
- ΔGEN +$106.7K
- TOP1 96.8%
- PY 2024
Volume peers
Nearest volume peer: Carestream Dental, LLC ($175.9K)
VisionCare Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
VisionCare Inc.'s CMS-reported General Payments increased by $106.7K (+154.9%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: SAMSARA VISIONPY2023: SAMSARA VISIONPY2024: VisionCare Inc.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $68,870.80
- PY2024
- $175,574.56
What the Data Shows for VisionCare Inc.
CMS Open Payments is not a single ledger: the all-tracks total shown above is General Payments plus Research Payments plus Ownership/Investment interests, each with its own disclosure rules. For VisionCare Inc. that figure is drawn almost entirely from the General Payments track (day-to-day consulting, meals, travel and speaking fees). Data for a given Program Year arrives roughly a year after the period it covers; our methodology page documents the release cadence and how we standardize the tracks for cross-company comparison.
6 transactions worth $170.1K make "Consulting Fee" the top general-payment category in the 2-category breakdown below, 96.9% of General Payments (see our methodology for how research and ownership payments are reported separately).
General Payment Breakdown by Type
Across 2 types of general payments, VisionCare Inc.'s largest category was "Consulting Fee" at $170.1K - 96.9% of General Payments.
How VisionCare Inc. divides its payments
Top payment categories by total reported dollar volume
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Consulting Fee | $170.1K | 6 | 96.9% |
| Food and Beverage | $5.5K | 80 | 3.1% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $171,957.80 (97.9%) of $175,574.56 in this company's General Payments records across 34 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for VisionCare Inc.
The five named recipients with the highest reported General Payments from this company
- 1
Jonathan H. Talamo
$170,000.00 across 2 reported transactions
- 2
Carlos E. Martinez
$996.78 across 12 reported transactions
- 3
Garvin H. Davis
$355.34 across 6 reported transactions
- 4
Francis R. Lamy
$345.10 across 2 reported transactions
- 5
Rajiv R. Rathod
$260.58 across 2 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
VisionCare Inc. ranks #1044 of 1,925 by total payments (bottom 46% by spend) but is notably more concentrated than that alone would suggest -- #160 of 1,838 by HHI (top 9% most concentrated). Its payments land on an unusually narrow set of recipients for its spend size.
View all 12 companies in this HHI neighborhood as a list
- Henry Schein, Inc. : $27.4M total payments, HHI 9520
- Sonavex, Inc. : $61.8K total payments, HHI 9490
- Fujirebio Diagnostics, Incorporated : $2.1M total payments, HHI 9489
- Sensible Medical Innovations Inc : $37.1K total payments, HHI 9459
- Biolife, L.L.C. : $7.9K total payments, HHI 9454
- BSN Medical Inc : $445.4K total payments, HHI 9445
- VisionCare Inc. (this company) : $175.6K total payments, HHI 9376
- Ziemer USA : $62.1K total payments, HHI 9354
- AstraZeneca AB : $1.6M total payments, HHI 9332
- Synapse Biomedical Inc : $193.9K total payments, HHI 9301
- Brahms GmbH : $71.8K total payments, HHI 9287
- VisionAir Solutions, LLC : $81.4K total payments, HHI 9154
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as VisionCare Inc.'s, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about VisionCare Inc..
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with VisionCare Inc..
Showing 6 of 1,924 companies with CMS-reported payment data.
Barco, Inc.
$175.3K 66 recipients
Compare payment profiles
GS Solutions, Inc.
$175.2K 82 recipients
Compare payment profiles
Dmg America LLC
$176.1K 305 recipients
Compare payment profiles
Optellum Ltd
$176.8K 0 recipients
Compare payment profiles
Foundation Fusion Solutions, LLC
$177.0K 1,772 recipients
Compare payment profiles
Put this to use
VisionCare Inc. ranks #1044 of 1,925 by all-tracks total payments, led by "Consulting Fee".
- See how manufacturer spending compares across the full leaderboard. Top 100 by total payments
- Compare "Consulting Fee" spend across every manufacturer, not just VisionCare Inc.. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.